Researchers found a new enzyme in leishmaniasis parasites that could lead to better treatments.

Researchers at the University of Kansas have discovered a new pathway in parasites that cause human leishmaniasis, a disease affecting about 1 million people annually. This breakthrough identifies the CYP5122A1 enzyme, which is crucial for the parasite's ergosterol production. Previously, azole antifungal drugs were ineffective, but targeting this new pathway could lead to more effective treatments for leishmaniasis.

3 months ago
4 Articles